Suchergebnisse - "Venkatakrishnan, Karthik"

PubPharm (18)

1

Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

enthalten in: Journal of clinical pharmacology | 2022

von Zhou, X. | Mould, D. | Yuan, Y. | +4

2

Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2020

von Pusalkar, S. | Zhou, X. | Li, Y. | +8

3

Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction

enthalten in: Journal of clinical pharmacology | 2019

von Zhou, X. | Lockhart, A. | Fu, S. | +6

4

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2019

von Zhou, X. | Pusalkar, S. | Chowdhury, S. | +4

5

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von O'Connor, O. | Özcan, M. | Jacobsen, E. | +27

6

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2019

von Falchook, G. | Coleman, R. | Roszak, A. | +23

CommentIn: JAMA Oncol. 2019 Jun 1;5(6):910-911. - PMID 31021370

7

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Kelly, K. | Friedberg, J. | Park, S. | +22

8

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

enthalten in: Investigational new drugs | 2018

von Zhou, X. | Pant, S. | Nemunaitis, J. | +10

9

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

enthalten in: Investigational new drugs | 2018

von Zhou, X. | Nemunaitis, J. | Pant, S. | +8

10

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients : rationale for lower dosage in Asia

enthalten in: British journal of clinical pharmacology | 2018

von Zhou, X. | Mould, D. | Takubo, T. | +4